Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study - Report - MDSpire
Advertisement
Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study
Efficacy and Safety of Fidaxomicin in IBD Patients with Clostridioides difficile Infection
Overview
In a multicenter retrospective study of 96 IBD patients treated with fidaxomicin for CDI, the recurrence rate at 8 weeks was 10%, with an 82% sustained response at 12 weeks. Fidaxomicin was well tolerated and showed greater effectiveness in patients experiencing their first CDI episode, potentially improving short-term IBD outcomes.
Background
Patients with inflammatory bowel disease (IBD) have a significantly increased risk of Clostridioides difficile infection (CDI), which can lead to worsened clinical outcomes including therapy escalation and colectomy. Current guidelines recommend vancomycin or fidaxomicin for CDI treatment, but data on fidaxomicin use specifically in IBD patients are limited. Understanding fidaxomicin's efficacy and safety in this population is important to optimize management and potentially improve IBD disease course.
Data Highlights
Outcome
Result
Number of patients
96 (57 UC, 39 CD)
CDI recurrence rate at 8 weeks
10%
Sustained response at 12 weeks
82%
Recurrence rate in first CDI episode patients
4.3%
Recurrence rate in patients with previous CDI
16%
IBD therapy escalation within 30 days
48% overall; 12% in sustained responders vs 20% in non-responders
Colectomy (UC patients)
5 patients
Adverse events
1 moderate, 5 mild
Mortality
1 death unrelated to CDI or IBD
Key Findings
Fidaxomicin treatment in IBD patients with CDI resulted in a low recurrence rate of 10% at 8 weeks.
Sustained response without CDI-targeted therapy was achieved in 82% of patients at 12 weeks.
Patients experiencing their first CDI episode had lower recurrence (4.3%) and higher sustained response (91%) compared to those with previous CDI episodes.
Nearly half of patients required escalation of IBD therapy within 30 days, with a trend toward less escalation in those achieving sustained CDI response.
Fidaxomicin was well tolerated, with only one moderate and five mild adverse events reported.
Five ulcerative colitis patients underwent colectomy; one death occurred but was unrelated to CDI or IBD.
Clinical Implications
Fidaxomicin is an effective and safe option for treating CDI in patients with IBD, particularly beneficial in those with a first CDI episode. Its use may reduce CDI recurrence and potentially limit the need for short-term escalation of IBD therapy. Clinicians should consider fidaxomicin as a preferred treatment to improve CDI outcomes and possibly influence IBD disease activity.
Conclusion
This large international cohort study supports fidaxomicin as a safe and effective treatment for CDI in IBD patients, with improved outcomes in CDI-naïve individuals and potential positive effects on short-term IBD management.
References
Efficacy and Safety of Fidaxomicin in Treating Clostridioides difficile Infection Among Inflammatory Bowel Disease Patients: A Multicenter Retrospective Analysis
Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.
